{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:09:42Z","timestamp":1794427782749,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["21YF1406300"],"award-info":[{"award-number":["21YF1406300"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth Foundation of Zhongshan hospital Fudan University","award":["2021ZSQNN61"],"award-info":[{"award-number":["2021ZSQNN61"]}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["22ZR1411400"],"award-info":[{"award-number":["22ZR1411400"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02356-y","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:57:11Z","timestamp":1744804631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical benefit loss in myeloma patients declining autologous stem cell transplantation: a real-world study"],"prefix":"10.1007","volume":"16","author":[{"given":"Yue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"10272","key":"2356_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"9","key":"2356_CR2","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","volume":"32","author":"M Gavriatopoulou","year":"2018","unstructured":"Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883\u201398.","journal-title":"Leukemia"},{"issue":"8","key":"2356_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"issue":"9","key":"2356_CR4","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.bbmt.2020.04.016","volume":"26","author":"L Garderet","year":"2020","unstructured":"Garderet L, Morris C, Beksac M, Gahrton G, Schonland S, Yakoub-Agha I, et al. Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? A review from the chronic malignancies working party of the EBMT. Biol Blood Marrow Transplant. 2020;26(9):1559\u201366.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2356_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101929","volume":"82","author":"I Ntanasis-Stathopoulos","year":"2020","unstructured":"Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82: 101929.","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"2356_CR6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and dexamethasone with transplantation for Myeloma. N Engl J Med. 2017;376(14):1311\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"2356_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in Myeloma. N Engl J Med. 2022;387(2):132\u201347.","journal-title":"N Engl J Med"},{"issue":"3","key":"2356_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","volume":"4","author":"D Binod","year":"2018","unstructured":"Binod D, Aniko S, Saurabh C, Mehdi H, Anita DS, Saad ZU, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):343\u201350.","journal-title":"JAMA Oncol"},{"issue":"12","key":"2356_CR9","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1038\/s41409-021-01431-6","volume":"56","author":"LP Xu","year":"2021","unstructured":"Xu LP, Lu PH, Wu DP, Sun ZM, Liu QF, Han MZ, et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplant. 2021;56(12):2940\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2356_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.55","volume":"4","author":"J Lu","year":"2014","unstructured":"Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4(8): e239.","journal-title":"Blood Cancer J"},{"issue":"33","key":"2356_CR11","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976\u201384.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2356_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","volume":"21","author":"N Shah","year":"2015","unstructured":"Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21(7):1155\u201366.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2356_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ajh.25797","volume":"95","author":"A Belotti","year":"2020","unstructured":"Belotti A, Ribolla R, Cancelli V, Crippa C, Bianchetti N, Ferrari S, et al. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65\u201375 years. Am J Hematol. 2020;95(7):759\u201365.","journal-title":"Am J Hematol"},{"issue":"3","key":"2356_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","volume":"54","author":"WI Gonsalves","year":"2019","unstructured":"Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a mayo stratification of Myeloma and risk-adapted therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019;54(3):353\u201367.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2356_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295\u2013308.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2356_CR16","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international Myeloma working group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood"},{"issue":"4","key":"2356_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11(4):83.","journal-title":"Blood Cancer J"},{"issue":"28","key":"2356_CR18","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blade","year":"2011","unstructured":"Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805\u201312.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2356_CR19","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2009.122","volume":"23","author":"A Palumbo","year":"2009","unstructured":"Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23(10):1716\u201330.","journal-title":"Leukemia"},{"issue":"9","key":"2356_CR20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia"},{"issue":"8","key":"2356_CR21","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2356_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345.","journal-title":"Blood"},{"issue":"11","key":"2356_CR23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2356_CR24","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456\u201368.","journal-title":"Lancet Haematol"},{"issue":"10301","key":"2356_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"issue":"1","key":"2356_CR26","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","volume":"12","author":"R Mina","year":"2025","unstructured":"Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, et al. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. Lancet Haematol. 2025;12(1):e45\u201356.","journal-title":"Lancet Haematol"},{"issue":"11","key":"2356_CR27","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(11):e890\u2013901.","journal-title":"Lancet Haematol"},{"issue":"1","key":"2356_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"R Mina","year":"2023","unstructured":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24(1):64\u201376.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2356_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70573","volume":"14","author":"X Dou","year":"2025","unstructured":"Dou X, Ren J, Li J, Liu X, Bao L, Chen Y, et al. Tandem versus single autologous stem cell transplantation for high-risk multiple myeloma in the era of novel agents: a real-world study of china. Cancer Med. 2025;14(1): e70573.","journal-title":"Cancer Med"},{"issue":"9","key":"2356_CR30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jtct.2024.06.030","volume":"30","author":"CP Venner","year":"2024","unstructured":"Venner CP, Duggan P, Song K, Reece D, Sharma S, Su J, et al. Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients in the maintenance era: real-world results from the canadian myeloma research group database. Transplant Cell Ther. 2024;30(9):889\u2013901.","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2356_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. 2019;37(7):589\u201397.","journal-title":"J Clin Oncol"},{"key":"2356_CR32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139689","author":"P Duggan","year":"2020","unstructured":"Duggan P, Reece DE, Song K, Jimenez-Zepeda V, McCurdy A, Louzada ML, et al. Is Tandem ASCT needed in MM patients with high risk cytogenetics in the era of maintenance therapy? Results from the Canadian Myeloma Research Group (CMRG) database. Blood. 2020. https:\/\/doi.org\/10.1182\/blood-2020-139689.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02356-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02356-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02356-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:57:12Z","timestamp":1744804632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02356-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2356"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02356-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki, approved by the Ethics Committee of Zhongshan Hospital Fudan University (No. B2017-031R).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"534"}}